P/E at 29.79 vs Industry's 37.19: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry P/E

Dr Reddys Laboratories Ltd trades at a P/E multiple of 29.79, which is approximately 20% below the Pharmaceuticals & Biotechnology industry average of 37.19. This discount suggests the market is pricing in either slower growth prospects or elevated risks relative to peers. The mid-cap stock’s market capitalisation stands at ₹97,081.14 crores, positioning it well within the sector but not among the largest players. The valuation gap raises the question of whether the discount reflects a value opportunity or a justified caution — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? Investors should consider how this valuation compares with the company’s recent performance and technical indicators.

Performance Across Timeframes: Divergent Momentum

The stock’s returns over various periods reveal a mixed momentum profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 4.63%, underperforming the Sensex’s 2.37% loss. The year-to-date return is also negative at -8.49%, slightly worse than the Sensex’s -7.66%. More strikingly, the three-month and one-month returns are down 12.08% and 15.38% respectively, while the Sensex gained 2.31% and 1.19% in the same periods. This sharp short-term underperformance contrasts with a relatively modest longer-term decline, signalling recent headwinds. The one-week and one-day performances show some recovery, with gains of 1.06% and 1.35%, outpacing the Sensex’s 2.41% and 0.76% respectively. The 4-day consecutive gain streak, yielding a 3.46% rise, may indicate a short-term bounce — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Mixed Technical Signals

The technical picture for Dr Reddys Laboratories Ltd is nuanced. The stock currently trades above its 5-day moving average but remains below the 20-day, 50-day, 100-day, and 200-day moving averages. This configuration suggests a short-term upward momentum within a broader downtrend. The inability to surpass longer-term moving averages indicates resistance levels that have yet to be overcome, reflecting lingering bearish sentiment. The recent gap-up opening of 2.38% and intraday high of ₹1174.95 reinforce the short-term strength, but the longer-term trend remains under pressure. Such a setup often precedes a critical test of trend direction — is this a recovery or a dead-cat bounce?

Sector Performance Context

The Pharmaceuticals & Biotechnology sector has seen mixed results recently. Among 10 stocks that declared results, five posted positive outcomes, four were flat, and one was negative. This balanced sector performance contrasts with Dr Reddys Laboratories Ltd’s underwhelming returns over the past year and shorter periods. The sector’s average P/E of 37.19 reflects generally higher valuations, which Dr Reddys Laboratories Ltd trades below, indicating a relative valuation discount. This divergence raises the question of whether the stock’s recent struggles are company-specific or symptomatic of broader sector challenges — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Rating Reassessment and Historical Performance

Previously rated Hold by MarketsMOJO, Dr Reddys Laboratories Ltd had its rating updated on 13 Jul 2026. The current Mojo Score stands at 36.0 with a Sell grade, reflecting a reassessment based on recent data. Historically, the stock’s longer-term returns have lagged the Sensex significantly: a 3-year return of 2.81% versus the Sensex’s 20.61%, a 5-year return of 23.18% against 46.20%, and a 10-year return of 97.68% compared to 184.10%. These figures underscore a persistent underperformance trend over extended periods, which may justify the valuation discount and rating revision.

Intraday and Short-Term Trading Activity

On 3 Aug 2026, Dr Reddys Laboratories Ltd outperformed its sector by 1.33%, with a day gain of 1.35% and an opening gap up of 2.38%. The stock’s intraday high reached ₹1174.95, maintaining this level throughout the session. This short-term strength contrasts with the broader negative momentum seen over the past month and quarter, suggesting active trading interest and possible technical support near current levels. The four-day consecutive gain streak, accumulating 3.46%, may be an early sign of a shift in sentiment, though the longer-term moving averages remain a hurdle.

What the Data Collectively Shows

The valuation discount of Dr Reddys Laboratories Ltd relative to its sector, combined with its underperformance across multiple timeframes, paints a cautious picture. The short-term technical bounce above the 5-day moving average is encouraging but remains insufficient to reverse the longer-term downtrend indicated by the stock’s position below all major moving averages. The sector’s mixed results and higher average valuations further highlight the stock’s relative weakness. The rating update from Hold to Sell by MarketsMOJO reflects these factors, emphasising the need for investors to carefully weigh valuation against recent performance and technical signals — what is the current rating for Dr Reddys Laboratories Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →